MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.

Skarin N, Hallbeck M, Werlenius K, Rohan Z, Sandström M, Turanyi E, Löfgren D, Johansson H, Strandéus M, Tavelin B, Malmström A.

Open source

DOI: 10.1007/s11060-026-05633-0
Published: 2026-05-20
Container: J Neurooncol
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11060-026-05633-0,
  title = {MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.},
  author = {Skarin N and  Hallbeck M and  Werlenius K and  Rohan Z and  Sandström M and  Turanyi E and  Löfgren D and  Johansson H and  Strandéus M and  Tavelin B and  Malmström A.},
  year = {2026},
  journal = {J Neurooncol},
  doi = {10.1007/s11060-026-05633-0},
  url = {https://doi.org/10.1007/s11060-026-05633-0}
}

RIS

TY  - JOUR
TI  - MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.
AU  - Skarin N
AU  -  Hallbeck M
AU  -  Werlenius K
AU  -  Rohan Z
AU  -  Sandström M
AU  -  Turanyi E
AU  -  Löfgren D
AU  -  Johansson H
AU  -  Strandéus M
AU  -  Tavelin B
AU  -  Malmström A.
PY  - 2026
JO  - J Neurooncol
DO  - 10.1007/s11060-026-05633-0
UR  - https://doi.org/10.1007/s11060-026-05633-0
ER  -

APA

N, S., M, H., K, W., Z, R., M, S., E, T., D, L., H, J., M, S., B, T., & A., M. (2026). MGMT promoter methylation status for glioblastoma: defining the clinically relevant cut-off value for pyrosequencing.. J Neurooncol. https://doi.org/10.1007/s11060-026-05633-0

Source records

europe-pmc · retrieved 2026-09-26T04:01:58.106Z